ราคาเทียบกับมูลค่า
- Price
- $376.90
- Fair value
- $448.25
- Potential value
- $578.10
- As of
- 2026-09-18
เหตุผลที่มุมมองนี้อาจเป็นจริง
Accelerating clinical margin recovery in OptumHealth combined with commercial health benefit premium repricing that absorbs medical cost inflation, driving operating margins from 4.24% in FY2025 toward historical levels of 6.50% and expanding fair value toward Potential value of USD 578.10.
สิ่งที่จะเปลี่ยนมุมมองของเรา
CMS enacts unfavorable statutory Medicare Advantage rate adjustments or expands risk-adjustment audits.
We rate UnitedHealth Group a Buy. The company's massive scale in health benefits and integrated pharmacy services positions it for steady cash generation and earnings recovery, offering attractive upside from the report-date price to our Fair value.
Our rating is Buy. For an investor, this means UnitedHealth Group offers an attractive balance of steady compounding and share price appreciation, supported by leading positions in health benefits and healthcare services.
The report was prepared at a price of USD 376.90 on September 18, 2026. This price trades at a 15.92% discount to our Fair value of USD 448.25. If clinical care margins recover faster than expected, the shares could reach Potential value of USD 578.10.4